New: Introducing the Finviz Crypto Map

Learn More
Last Close
Jul 15 04:00PM ET
12.88
Dollar change
-0.47
Percentage change
-3.52
%
IndexRUT P/E- EPS (ttm)-1.50 Insider Own3.58% Shs Outstand69.58M Perf Week-0.54%
Market Cap904.86M Forward P/E- EPS next Y-1.25 Insider Trans- Shs Float67.74M Perf Month-1.68%
Enterprise Value658.03M PEG- EPS next Q-0.49 Inst Own109.16% Short Float10.22% Perf Quarter21.17%
Income-113.68M P/S9.69 EPS this Y5.82% Inst Trans28.03% Short Ratio14.72 Perf Half Y-2.57%
Sales93.38M P/B2.78 EPS next Y18.16% ROA-23.22% Short Interest6.93M Perf YTD-12.02%
Book/sh4.63 P/C3.41 EPS next 5Y-4.21% ROE-29.80% 52W High17.70 -27.23% Perf Year30.50%
Cash/sh3.78 P/FCF- EPS past 3/5Y26.71% 15.81% ROIC-33.42% 52W Low9.03 42.64% Perf 3Y98.15%
Dividend Est.- EV/EBITDA- Sales past 3/5Y41.95% 20.90% Gross Margin86.95% Volatility3.87% 3.72% Perf 5Y-65.45%
Dividend TTM- EV/Sales7.05 EPS Y/Y TTM15.96% Oper. Margin-115.26% ATR (14)0.51 Perf 10Y-
Dividend Ex-Date- Quick Ratio4.71 Sales Y/Y TTM85.05% Profit Margin-121.73% RSI (14)51.66 Recom1.57
Dividend Gr. 3/5Y- - Current Ratio4.71 EPS Q/Q27.42% SMA200.41% Beta1.26 Target Price22.17
Payout- Debt/Eq0.06 Sales Q/Q170.29% SMA504.64% Rel Volume0.69 Prev Close13.35
Employees286 LT Debt/Eq0.05 EarningsMay 08 AMC SMA200-2.16% Avg Volume470.54K Price12.88
IPOApr 28, 2017 Option/ShortYes / Yes EPS/Sales Surpr.56.11% 31.53% Trades Volume325,366 Change-3.52%
Date Action Analyst Rating Change Price Target Change
May-20-25Initiated TD Cowen Buy
Dec-16-24Upgrade JP Morgan Neutral → Overweight $18
Nov-07-24Upgrade Leerink Partners Market Perform → Outperform $10 → $25
Nov-01-24Downgrade Wells Fargo Overweight → Equal Weight $12
Mar-21-23Resumed Wells Fargo Overweight $12
Jan-04-23Reiterated H.C. Wainwright Neutral $10 → $8
Dec-20-22Upgrade Jefferies Hold → Buy $7.70 → $11
Nov-01-22Downgrade H.C. Wainwright Buy → Neutral $40 → $8
Oct-21-22Downgrade SVB Leerink Outperform → Mkt Perform $8
Oct-04-22Resumed Wells Fargo Overweight $45 → $9
Jul-10-25 12:00PM
Jun-20-25 12:00PM
Jun-04-25 09:55AM
May-30-25 06:00AM
May-22-25 05:00PM
06:00AM Loading…
May-21-25 06:00AM
May-19-25 04:15PM
May-14-25 09:55AM
May-08-25 05:50PM
04:05PM
May-07-25 10:35AM
Apr-30-25 06:33PM
Apr-28-25 05:33PM
10:48AM
Apr-25-25 01:00PM
06:00AM Loading…
Apr-21-25 06:00AM
Apr-17-25 06:00AM
Apr-09-25 10:13AM
Apr-05-25 11:00AM
Mar-26-25 06:00AM
Mar-25-25 04:30PM
10:49AM
Mar-05-25 04:05PM
Mar-04-25 07:09AM
Feb-26-25 06:00AM
Feb-25-25 06:00AM
Feb-18-25 06:00AM
Feb-13-25 06:00AM
Jan-30-25 06:00AM
Jan-08-25 04:05PM
08:30AM Loading…
Dec-12-24 08:30AM
08:30AM
Nov-21-24 06:05AM
06:00AM
Nov-05-24 06:00AM
Oct-31-24 04:05PM
Oct-30-24 09:14AM
Oct-29-24 06:00AM
Oct-25-24 06:00AM
Oct-21-24 06:00AM
Oct-10-24 06:30AM
Sep-19-24 12:08PM
Sep-18-24 06:00AM
Sep-03-24 04:30PM
Aug-22-24 06:30AM
Aug-01-24 04:10PM
04:05PM
Jul-30-24 06:30AM
Jul-25-24 04:30PM
Jul-22-24 06:00AM
Jul-11-24 06:30AM
Jun-17-24 06:00AM
Jun-10-24 06:00AM
May-28-24 06:30AM
May-19-24 09:00PM
May-16-24 04:20PM
May-02-24 04:05PM
Apr-30-24 06:00AM
Apr-11-24 06:00AM
Apr-10-24 09:35AM
Apr-08-24 06:00AM
Mar-28-24 06:00AM
Mar-27-24 06:00AM
Mar-22-24 12:00PM
Mar-11-24 12:44PM
Mar-09-24 01:09PM
Mar-07-24 06:39AM
Mar-06-24 10:53PM
04:09PM
Mar-05-24 04:30PM
Feb-28-24 10:00AM
Feb-27-24 06:00AM
Feb-14-24 06:00AM
Feb-09-24 08:00AM
Feb-08-24 06:00AM
Jan-31-24 06:00AM
Jan-11-24 12:00PM
Jan-04-24 06:15AM
06:00AM
Dec-26-23 08:00AM
Dec-15-23 08:30AM
Dec-08-23 10:11AM
Nov-30-23 08:30AM
Nov-08-23 05:33PM
Nov-07-23 04:05PM
Nov-01-23 08:30AM
Oct-17-23 08:30AM
Oct-16-23 04:30PM
Aug-10-23 04:05PM
Aug-01-23 08:30AM
Jul-19-23 08:30AM
Jul-03-23 08:30AM
Jun-29-23 04:05PM
Jun-26-23 08:30AM
Jun-02-23 06:41PM
Jun-01-23 08:30AM
May-18-23 08:30AM
May-08-23 04:05PM
May-01-23 08:30AM
Apr-18-23 04:05PM
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EcoR1 Capital, LLCDirectorMay 15 '25Buy11.4349,502565,84717,877,989May 19 06:35 PM
EcoR1 Capital, LLCDirectorMay 19 '25Buy11.785,91969,73817,883,908May 19 06:35 PM
EcoR1 Capital, LLCDirectorApr 16 '25Buy11.1673,953825,58917,773,727Apr 18 03:17 PM
EcoR1 Capital, LLCDirectorApr 17 '25Buy11.5254,760630,81917,828,487Apr 18 03:17 PM
EcoR1 Capital, LLCDirectorApr 04 '25Buy11.17196,4382,193,80017,699,774Apr 07 06:34 PM
EcoR1 Capital, LLCDirectorApr 03 '25Buy11.84120,7701,430,17017,503,336Apr 07 06:34 PM
EcoR1 Capital, LLCDirectorApr 02 '25Buy11.8574,360881,01717,382,566Apr 02 07:02 PM
EcoR1 Capital, LLCDirectorApr 01 '25Buy11.6048,658564,64717,308,206Apr 02 07:02 PM
EcoR1 Capital, LLCDirectorMar 31 '25Buy11.754,39751,65817,259,548Apr 02 07:02 PM
EcoR1 Capital, LLCDirectorMar 25 '25Buy12.9153,501690,45217,211,303Mar 27 06:53 PM
EcoR1 Capital, LLCDirectorMar 26 '25Buy12.2443,848536,85717,255,151Mar 27 06:53 PM
EcoR1 Capital, LLCDirectorMar 20 '25Buy12.9373,476949,88317,104,080Mar 24 05:45 PM
EcoR1 Capital, LLCDirectorMar 21 '25Buy12.7831,033396,51817,135,113Mar 24 05:45 PM
EcoR1 Capital, LLCDirectorMar 24 '25Buy13.0822,689296,84717,157,802Mar 24 05:45 PM
EcoR1 Capital, LLCDirectorMar 18 '25Buy12.65113,8801,440,85516,972,298Mar 19 06:32 PM
EcoR1 Capital, LLCDirectorMar 19 '25Buy12.6458,306737,23317,030,604Mar 19 06:32 PM
EcoR1 Capital, LLCDirectorMar 17 '25Buy12.2356,277688,46516,858,418Mar 19 06:32 PM
EcoR1 Capital, LLCDirectorMar 13 '25Buy12.48468,3565,847,23716,802,141Mar 13 07:35 PM
EcoR1 Capital, LLCDirectorMar 11 '25Buy11.49320,6903,685,85116,040,851Mar 13 07:35 PM
EcoR1 Capital, LLCDirectorMar 12 '25Buy12.25292,9343,587,82616,333,785Mar 13 07:35 PM
EcoR1 Capital, LLCDirectorJan 16 '25Buy13.88121,6811,689,54115,700,413Jan 21 05:34 PM
EcoR1 Capital, LLCDirectorJan 17 '25Buy13.8719,748273,99815,720,161Jan 21 05:34 PM
EcoR1 Capital, LLCDirectorJan 13 '25Buy13.3974,125992,87515,485,203Jan 15 06:12 PM
EcoR1 Capital, LLCDirectorJan 14 '25Buy13.5654,500739,26515,539,703Jan 15 06:12 PM
EcoR1 Capital, LLCDirectorJan 15 '25Buy14.0139,029546,67115,578,732Jan 15 06:12 PM
EcoR1 Capital, LLCDirectorJan 10 '25Buy13.13204,0982,678,99015,411,078Jan 10 06:27 PM
EcoR1 Capital, LLCDirectorJan 08 '25Buy14.0721,021295,82915,206,980Jan 10 06:27 PM
Moore Paul AndrewChief Scientific OfficerJan 06 '25Option Exercise0.0037,166034,741Jan 06 08:35 PM
Moore Paul AndrewChief Scientific OfficerJan 06 '25Sale14.9221,200316,39114,741Jan 06 08:35 PM
Galbraith KennethChair & CEOJan 06 '25Option Exercise0.00114,3320114,209Jan 06 08:34 PM
Galbraith KennethChair & CEOJan 06 '25Sale14.9257,291855,01747,543Jan 06 08:34 PM
Smith Jeffrey T LEVP & Chief Medical OfficerJan 06 '25Option Exercise0.0020,000020,000Jan 06 08:19 PM
Smith Jeffrey T LEVP & Chief Medical OfficerJan 06 '25Sale14.9211,110165,8078,890Jan 06 08:19 PM
Smith Jeffrey T LOfficerJan 06 '25Proposed Sale14.4611,110160,651Jan 06 07:50 PM
Moore Paul AndrewOfficerJan 06 '25Proposed Sale14.4621,200306,552Jan 06 07:43 PM
Galbraith, KennethOfficerJan 06 '25Proposed Sale14.4657,291828,428Jan 06 07:37 PM
EcoR1 Capital, LLCDirectorJan 02 '25Buy14.78157,8802,333,40315,185,959Jan 02 05:51 PM
EcoR1 Capital, LLCDirectorDec 31 '24Buy14.57146,5012,134,44615,028,079Jan 02 05:51 PM
EcoR1 Capital, LLCDirectorDec 30 '24Buy14.4758,988853,32614,881,578Jan 02 05:51 PM
EcoR1 Capital, LLCDirectorDec 27 '24Buy14.49101,6591,473,18114,822,590Dec 27 06:41 PM
EcoR1 Capital, LLCDirectorDec 26 '24Buy14.3816,692240,03814,720,931Dec 27 06:41 PM
EcoR1 Capital, LLCDirectorDec 24 '24Buy14.1211,958168,89614,704,239Dec 27 06:41 PM